Orphan drug status is approved for a promising vaccine to control brain cancer, specifically glioblasoma, tumor growth and recurrence. Scientists at Roswell Park Cancer Institute developed the vaccine and Roswell Park spinoff company MimiVax LLC was informed of FDA approval. SurVaxM, also known as DRU-2017-5947, is an immunotherapy drug that targets survivin, a cell-survival protein present in most cancers. The drug actually is an engineered molecule that can stimulate the immune system in a number of different ways to recognize and kill cancer cells. The molecule’s target, survivin, is present in many different types of cancer and it is expected that the drug potentially may have broad application against cancer.